Shots:

• The company initiates the P-III (CONTERNO) study to evaluate cosibelimab (1200mg, q3w) + CT vs CT alone in a ratio (2:1) in 560 patients with previously untreated stage IV non-sq. NSCLC with no EGFR mutations or ALK translocations
• The 1EPs of the trial is OS & 2EPs include PFS, ORR & safety. The study is designed to support full regulatory approvals globally
• Cosibelimab is currently being evaluated in an ongoing P-I trial in naïve patients with selected recurrent or metastatic cancers including LA & metastatic cutaneous SCC & plans to support one or more applications for marketing approval. The company is also evaluating CK-101 for EGFR mutation-positive NSCLC

Ref: Globe Newswire | Image: Checkpoint